Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00456014 · ClinicalTrials.gov registry record · NA

Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment

A NA study of Depression, sponsored by New York State Psychiatric Institute.

Completed
Registry status
NA
Development phase
37
Enrollment target
1
Study location

NCT00456014: Completed NA study of Depression, sponsored by New York State Psychiatric Institute.

NCT00456014 is a NA study of Depression that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 37 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00456014, a NA study of Depression, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
NA
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.

Primary Outcome

Remission in this study is defined as both a ≥50% decrease in the 24-item Hamilton Depression Rating Scale (HDRS) Score and a final 24-item HDRS score \<10. Remission of depressive symptoms was calculated for the 28 completers of the SSRI phase.

Conditions Studied

Interventions

  • DRUG Escitalopram
  • DRUG Desipramine

Study Locations (1)

New York

  • Columbia University/New York State Psychiatric Institute - New York

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2006-09
Est. Completion 2012-05
Phase NA

What the finished NCT00456014 record still lists

NCT00456014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Escitalopram is the first listed.

NCT00456014 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00456014 about?

NCT00456014 is a clinical study titled "Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment". This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.

What is the current status of trial NCT00456014?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2006-09. Estimated completion is 2012-05.

What conditions does trial NCT00456014 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00456014?

The interventions under investigation include: Escitalopram (DRUG), Desipramine (DRUG).

Who is sponsoring clinical trial NCT00456014?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00456014 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00456014's enrollment target sits among peer trials

37 535th of 679 higher than 143 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00456014, the US trial registry maintained by the National Library of Medicine. NCT00456014 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.